$KLRA
Kailera Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$13.00
▲+0.62%+$0.080
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateKailera Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is KLRA up today? It is at $13.00 (+0.62%), and our scanner flagged it 97 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KLRA spikes, and full due diligence on KLRA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $KLRA 97 times in the last 30 days. Create a free account to track $KLRA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on KLRA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KLRA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystKailera Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Sep 9, 2026 · 11 days agoAcross every filing on file, supply equal to 271.5% of the tradeable float is in play - 271.5% more can still be issued.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
43,750,000 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $700.0M in size · Priced at $16/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Renaud Ronald C Jr Officer | Other | 38K 0.03% of company | n/a | 38K | $200K at $5.25 | Jun 9, 26 |
Kaplan Andrew T. Director | Acquired (grant/award) | +17.86M 13.8% of company | n/a | 17.86M | n/a | Apr 20, 26 |
Kaplan Andrew T. Director | Bought (open market) | +8.40M 6.5% of company | added 47% | 26.26M | $134.4M at $16.00 | Apr 20, 26 |
Bain Capital Life Sciences Investors, Llc Beneficial Owner (10%) | Acquired (grant/award) | +21.02M 16.2% of company | n/a | 21.02M | n/a | Apr 20, 26 |
Bain Capital Life Sciences Investors, Llc Beneficial Owner (10%) | Bought (open market) | +1.56M 1.2% of company | added 7.4% | 22.58M | $25.0M at $16.00 | Apr 20, 26 |
Koppel Adam Director | Acquired (grant/award) | +21.02M 16.2% of company | n/a | 21.02M | n/a | Apr 20, 26 |
Koppel Adam Director | Bought (open market) | +1.56M 1.2% of company | added 7.4% | 22.58M | $25.0M at $16.00 | Apr 20, 26 |
Bain Capital Investors Llc Beneficial Owner (10%) | Acquired (grant/award) | +17.86M 13.8% of company | n/a | 17.86M | n/a | Apr 20, 26 |
Bain Capital Investors Llc Beneficial Owner (10%) | Bought (open market) | +8.40M 6.5% of company | added 47% | 26.26M | $134.4M at $16.00 | Apr 20, 26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Beneficial Owner (10%) | Acquired (grant/award) | +11.51M 8.9% of company | n/a | 9.48M | n/a | Apr 20, 26 |
Rtw Investments, Lp Beneficial Owner (10%) | Acquired (grant/award) | +10.28M 7.9% of company | n/a | 10.28M | n/a | Apr 20, 26 |
Rtw Investments, Lp Beneficial Owner (10%) | Bought (open market) | +500K 0.4% of company | added 4.9% | 10.78M | $8.0M at $16.00 | Apr 20, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on KLRA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KLRA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
KLRA last traded at $13.00, up 0.62% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Kailera Therapeutics, Inc. Common Stock (KLRA) is next expected to report earnings on Wednesday, November 11, 2026, about 52 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The KLRA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KLRA 97 times in the last 30 days.
KLRA (Kailera Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $1.66B in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KLRA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$KLRA discussion
Sign in to ask a question or join the discussion.